Administration of Cholic Acid Inhibits Equol Production from Daidzein in Mice

• Published in: Journal of Nutritional Science and Vitaminology 2020/12/31, Vol.66(6), pp.571-576
• Main Authors: YOSHIOKA, Hiroko, WATANABE, Masamichi, NANBA, Fumio, SUZUKI, Toshio, FUKIYA, Satoru, YOKOTA, Atsushi, TODA, Toshiya
• Format: Article
• Language: English
• Subjects: bile acid; daidzein metabolite; deoxycholic acid; gut microbiota; isoflavone
• ISSN: 0301-4800; 1881-7742
• DOI: 10.3177/jnsv.66.571

Equol (Eq) is a metabolite of soy isoflavone daidzein (De) produced by the intestinal microbiota. The clinical effectiveness of soy isoflavone is considered to depend on the individual ability of Eq production. Previous studies have demonstrated that habitual dietary patterns may influence the production of Eq. For example, high Eq producers consumed less fat as a percentage of energy than low Eq producers. However, the inhibitory factors of Eq production are unknown. Recently, it was reported that bile acids induced by high-fat diet consumption may be a host-related factor controlling the composition of the intestinal microbiota. In this study, we investigated the effect of cholic acid (CA) administration, a mimic of the microbiota altered by a high-fat diet, on Eq production in mice. CA administration significantly decreased the levels of the De metabolites Eq, dihydrodaidzein, and O-desmethylangolensin in the serum of mice. However, CA administration did not affect the total molar concentration of De and its metabolites. Moreover, CA administration increased the levels of secondary bile acids, particularly deoxycholic acid (DCA), which has strong antibacterial activity in the cecum contents of mice. Thus, CA administration may increase the levels of DCA, a secondary bile acid, resulting in inhibition of Eq production. These findings may help to reveal the factors inhibiting Eq production and enhance the clinical effectiveness of isoflavone intake.